Suchergebnisse - "Farinati, Fabio"

PubPharm (9)

1

Erratum to: Oxidative DNA damage correlates with cell immortalization and mir-92 expression in hepatocellular carcinoma

enthalten in: BMC cancer | 2014

von Cardin, R. | Piciocchi, M. | Sinigaglia, A. | +8

2

Erratum to: Oxidative DNA damage correlates with cell immortalization and mir-92 expression in hepatocellular carcinoma

enthalten in: BMC cancer | 2014

von Cardin, R. | Piciocchi, M. | Sinigaglia, A. | +8

3

Oxidative DNA damage correlates with cell immortalization and mir-92 expression in hepatocellular carcinoma

enthalten in: BMC cancer | 2012

von Cardin, R. | Romilda, C. | Piciocchi, M. | +19

ErratumIn: BMC Cancer. 2014;14:284 multiple author names corrected

4

Early and very early hepatocellular carcinoma : when and how much do staging and choice of treatment really matter? A multi-center study

enthalten in: BMC cancer | 2009

von Farinati, F. | Sergio, A. | Baldan, A. | +10

5

Early and very early hepatocellular carcinoma: when and how much do staging and choice of treatment really matter? A multi-center study

enthalten in: BMC cancer | 2009

von Farinati, F. | Sergio, A. | Baldan, A. | +10

6

Early and very early hepatocellular carcinoma: when and how much do staging and choice of treatment really matter? A multi-center study

enthalten in: BMC cancer | 2009

von Farinati, F. | Sergio, A. | Baldan, A. | +10

7

Tumor marker utility and prognostic relevance of cathepsin B, cathepsin L, urokinase-type plasminogen activator, plasminogen activator inhibitor type-1, CEA and CA 19-9 in colorectal cancer

enthalten in: BMC cancer | 2008

von Herszényi, L. | Farinati, F. | Cardin, R. | +6

8

Tumor marker utility and prognostic relevance of cathepsin B, cathepsin L, urokinase-type plasminogen activator, plasminogen activator inhibitor type-1, CEA and CA 19-9 in colorectal cancer

enthalten in: BMC cancer | 2008

von Herszényi, L. | Farinati, F. | Cardin, R. | +6

9

Tumor marker utility and prognostic relevance of cathepsin B, cathepsin L, urokinase-type plasminogen activator, plasminogen activator inhibitor type-1, CEA and CA 19-9 in colorectal cancer

enthalten in: BMC cancer | 2008

von Herszényi, L. | Farinati, F. | Cardin, R. | +6

1
[1]